Cantor Fitzgerald Has Lowered Expectations for Humana (NYSE:HUM) Stock Price

Humana (NYSE:HUM) had its price objective lowered by investment analysts at Cantor Fitzgerald from $290.00 to $201.00 in a research report issued to clients and investors on Thursday,MarketScreener reports. The firm presently has a “neutral” rating on the insurance provider’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 15.09% from the company’s current price.

Several other research analysts have also commented on HUM. Zacks Research lowered shares of Humana from a “hold” rating to a “strong sell” rating in a report on Thursday, January 1st. Sanford C. Bernstein reissued an “outperform” rating and issued a $344.00 price objective on shares of Humana in a research report on Tuesday, January 6th. Royal Bank Of Canada downgraded shares of Humana from an “outperform” rating to a “sector perform” rating and set a $189.00 target price on the stock. in a research note on Thursday. Evercore ISI decreased their price target on shares of Humana from $260.00 to $180.00 in a research report on Thursday. Finally, Jefferies Financial Group cut their price objective on Humana from $313.00 to $310.00 and set a “buy” rating on the stock in a research report on Monday, January 26th. Seven equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and five have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $263.05.

Humana Price Performance

Shares of Humana stock opened at $174.65 on Thursday. The business’s fifty day moving average price is $247.61 and its 200 day moving average price is $261.75. Humana has a twelve month low of $169.61 and a twelve month high of $315.35. The company has a current ratio of 2.02, a quick ratio of 2.02 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $21.01 billion, a P/E ratio of 16.34, a PEG ratio of 1.50 and a beta of 0.44.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, topping the consensus estimate of ($4.01) by $0.05. The company had revenue of $32.64 billion during the quarter, compared to analyst estimates of $32.08 billion. Humana had a return on equity of 12.86% and a net margin of 1.02%.The firm’s revenue was up 11.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, research analysts anticipate that Humana will post 16.47 earnings per share for the current year.

Hedge Funds Weigh In On Humana

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Humana by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider’s stock worth $3,652,890,000 after acquiring an additional 106,030 shares during the last quarter. Dodge & Cox increased its holdings in Humana by 5.6% during the 2nd quarter. Dodge & Cox now owns 11,352,920 shares of the insurance provider’s stock worth $2,775,562,000 after purchasing an additional 597,705 shares during the last quarter. Capital International Investors raised its position in shares of Humana by 113.9% in the 4th quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock valued at $1,490,239,000 after purchasing an additional 3,097,571 shares in the last quarter. State Street Corp raised its position in shares of Humana by 1.1% in the 2nd quarter. State Street Corp now owns 5,377,390 shares of the insurance provider’s stock valued at $1,319,334,000 after purchasing an additional 58,094 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Humana by 28.9% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,496,775 shares of the insurance provider’s stock valued at $1,151,759,000 after buying an additional 1,008,514 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

More Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Management projects ~25% Medicare Advantage membership growth in 2026 — scale gains could boost revenue and long‑term franchise value if margins recover. Humana outlines 25% Medicare Advantage membership growth for 2026
• Positive Sentiment: Revenue beat: Q4 revenue rose ~11% y/y to ~$32.6B, helped by CenterWell performance — shows underlying top‑line momentum despite profitability headwinds. Humana Incurs Q4 Loss, Revenues Up Y/Y on CenterWell Unit Strength
• Neutral Sentiment: Q4 EPS (non‑GAAP/adjusted context) slightly beat consensus but the company still reported a substantial GAAP loss; investors need to parse adjusted metrics vs. GAAP. Humana Reports Fourth Quarter 2025 Financial Results
• Negative Sentiment: FY‑2026 EPS guidance set at $9.00 vs. consensus ~$12.03 — a material cut to near‑term profitability expectations and the main driver of the stock decline. Humana forecasts 2026 profit below estimates
• Negative Sentiment: Lower quality (Star) ratings and Medicare Advantage rate pressure are expected to reduce margins and government benchmarks for plan payments — a structural headwind for 2026 results. Humana forecasts 2026 profit pressure as lower quality ratings weigh
• Negative Sentiment: Rising medical costs drove a widened Q4 GAAP loss (reported as roughly $796M in some coverage), adding to near‑term margin pressure. Humana Stock Falls on Disappointing Earnings Forecast
• Negative Sentiment: Market reaction: shares hit a 52‑week low and analysts are cautious, reflecting concern that reimbursement/rating dynamics and cost trends will keep profitability muted. Humana Hits 52-Week Low After Weak Profit Outlook

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.